Bactiguard has entered into partnership with Roeser Medical GmbH (“Roeser”) and signed an exclusive distribution agreement for Germany and Switzerland. At the same time, an order for products worth some EUR 400 000 has been placed and will be delivered throughout 2017. Bactiguard’s central European coverage has expanded significantly in...
Bactiguard outstanding bond loan was repaid in full on 12 December. The refinancing solution consists of loans totaling SEK 150 million. The bond loan Bactiguard issued in December 2011, with an initial nominal value of SEK 450 million, an annual interest rate of 11% and a duration of 5 years, matured on 12 December. The outstanding...
The call option program established by the main shareholders and aimed at key individuals in Bactiguard, matured on 30 November 2016. During the exercise period, a total of 688 000 B shares were acquired, corresponding to 2.07 percent of the capital and 0.99 percent of the votes, reducing the holdings of the main shareholders accordingly....
The Annual General Meeting of Bactiguard Holding AB (publ) will be held on Thursday, 18 May 2017 in Botkyrka. At the Annual General Meeting (AGM) in 2016, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall consist of four members. The chairman of the Board of Directors shall contact the three largest...
In the third quarter we report a continued positive trend in sales of our own portfolio of infection prevention products for the healthcare sector. We have delivered a total of approx. 284,000 products so far this year, an increase by approx. 260 percent. This means that we are already now close to our goal of at least doubling the...
In order to maintain financial flexibility after the repayment of the bond, and until a long-term financing solution is in place, the main shareholders of Bactiguard have issued a loan commitment of up to SEK 50 million Bactiguard has previously announced that it has secured the refinancing of the bond loan maturing December 12, 2016 through the...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday, November 10, 2016 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on November 10. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The...
Bactiguard has received a new major order from China of 100 000 Bactiguard coated Foley catheters for infection prevention We have received a new major order from our distributor in China, Jian An Pharmaceuticals. The order is for 100,000 BIP Foley catheters, which is the same quantity as the initial order received in early 2016. The order will...
Bactiguard expands its European presence in four new markets, by entering partnerships with Sanova Pharma for Austria, Pofam-Poznaǹ for Poland, Mediq Suomi for Finland and Inex Medical for Greece. “We are confident that combining Bactiguard’s portfolio for infection prevention, with the local expertise and reach of our partners, both in...
Bactiguard announces the launch of its new BIP Endotracheal Tube Evac, for prevention of ventilator associated pneumonia (VAP). It is one of a kind and designed to offer the best infection protection available on the market. VAP is the second most common nosocomial infection in the ICU, and associated with high-risk pathogens such as MRSA,...
A recent independent and randomized clinical study confirms that Bactiguard-coated Foley catheters reduce catheter associated urinary tract infections in ICU patients. The study was conducted at the King Fahad Hospital in Saudi Arabia and included 60 patients in the Intensive Care Unit (ICU), who were catheterized for at least 3...
Bactiguard has won a tender for urinary catheters covering the two Swedish counties Kronoberg and Blekinge. The contract is an extension of the previous agreement for 2 (+2)years which enable healthcare providers to purchase Bactiguard anti-infective urinary catheters. "This specific region has been using our products since 2012 and has now...
Bactiguard starts a new clinical trial that aims to reduce the risk of catheter associated urinary tract infections and the use of antibiotics in patients undergoing prostate cancer surgery in the well renowned Martini-Klinik of the University Medical Center Hamburg-Eppendorf. “In our never ending quest to improve the quality of life for our...
The positive trend with increased sales of our own portfolio of infection prevention products for the healthcare sector has continued and we delivered almost 110 000 units in the quarter. We have delivered a total of approximately 200 000 products so far this year, well above the total annual volume for 2015. License revenues are also back...
Bactiguard has received a new order from India of some 60 000 Foley catheters for infection prevention. The initial order from India, which was received in December 2015, consisted of some 50 000 Foley catheters for infection prevention (BIP Foleys). The new order consists of some 60 000 BIP Foleys and will generate direct sales...
The maturity of the credit facility of SEK 100 million that Bactiguard received as a loan commitment in November 2015, has been extended until 31 December, 2017 In November 2015 Bactiguard entered a credit facility agreement of SEK 130 million, consisting of a loan commitment of SEK 100 million and a renewal of bank overdraft facility of SEK 30...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday, August 11, 2016 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 11. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The...
The Executive Management in Bactiguard has been offered an opportunity to invest in the company by purchasing a sizeable number of shares. The Executive Management in Bactiguard has been offered an opportunity to invest in the company by purchasing a sizeable number of shares. Other members of senior management have also been offered the...
At Bactiguard Holding AB’s (publ) Annual General Meeting on May 19, the following resolutions were made: The Annual General Meeting adopted the income statement and balance sheet for 2015. It was decided that no dividend for the financial year 2015 will be paid and that the company's loss (for the year) will be carried forward....
Bactiguard started the year by increasing sales of its own product portfolio and delivered approx. 87,600 units, which is more than half of the total volume in 2015. License revenues were lower due to the adjusted order from C.R Bard, but as of March the order situation is back at a stable level. Operating profit was negative, but mayor payments...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Thursday, May 12, 2016 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 12. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and...
Repeated infections and subsequent antibiotic treatments are a painful part of daily life for patients with spinal cord injury, who use urinary catheters. Bactiguard and the Centre for Spinal Cord Injury are now starting a new clinical trial, which aims to increase the quality of life for these patients. “We are excited about the study and...
Bactiguard and BioInteractions have received a European research grant aimed at developing a new generation of vascular access catheters, with new bio-smart materials for medical devices. The technology will be developed in a joint project with BioInteractions, UK and Bactiguard, financed by VINNOVA and Innovate UK. Some of the most serious...
The annual report for Bactiguard Holding AB (publ) 2015 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 10 and can be ordered at info@bactiguard.se. This is information that Bactiguard Holding AB (publ) is...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Thursday, 19 May 2016 at 2:00 PM at the company´s office at Alfred Nobels Allé 150 in Tullinge. Registration commences at 1 PM. Right to participate and notice of intent to...
Bactiguard is exhibiting at Europe´s biggest annual congress for doctors specialized in urology, the European Association of Urology (EAU) Congress in Munich on March 11 – 14. Bactiguard’s infection prevention solution can be found in hall B, at booth number A03. Europe is one of our markets in focus and the EAU Congress offers a great...
2015 ended with the long-awaited product approval in China and a first order from India. As a result of large deliveries in the fourth quarter we doubled the total volume of units shipped, compared with the year before. An additional order from C.R. Bard generated additional revenue and strengthened the result. A new licensing deal opened...
Bactiguard Holding AB publishes the year end report for 2015 on Thursday February 18 at 08:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 18. CEO Christian Kinch and CFO Fredrik Järrsten will present the report and answer questions. The year end report will be available...
A laboratory study, recently published in the Journal of Biomedical Material, by scientists at Karolinska Institutet and Bactiguard, shows that Bactiguard’s coating can reduce the risk of a thrombosis. A previous clinical study shows that Bactiguard’s Infection Protection central venous catheters reduce the number of bloodstream infections by...
Following the Chinese approval of Bactiguard’s Foley catheters for infection prevention, which was recently announced, the company has received an initial order of 100,000 catheters. In January 2016, the doors were opened to China, one of the largest and fastest growing markets in the world, with the approval of the company's Foley catheter...
In January, Bactiguard exhibited for the first time at the Conference of Urological Society of India together with its Indian distributor Biorad Medisys Pvt Ltd. The congress was an important step in launching Bactiguard’s Infection Protection products in the Indian market. The annual Conference of Urological Society of India (USICON), arranged...
The product approval for Bactiguard's foley catheters for infection prevention in China, has now been announced by China Food and Drug Administration (CFDA). This opens the door to one of the largest and fastest growing markets in the world. ”Finally a breakthrough for Bactiguard in China. We started the approval process with CFDA already in...
